Use Caution/Monitor. imipramine, methylphenidate. Monitor BP. Methylphenidate may diminish antihypertensive effects. Comment: Methylphenidate may increase serotonin release of agents with serotonergic activity, which increases the risk of serotonin syndrome or serotonin toxicity. Avoid or Use Alternate Drug. Modify Therapy/Monitor Closely. By clicking send, you acknowledge that you have permission to email the recipient with this information. Monitor BP. 10mg (Aptensio XR, Ritalin LA, Metadate CD), 20mg (Aptensio XR, Ritalin LA, Metadate CD), 30mg (Aptensio XR, Ritalin LA, Metadate CD), 40mg (Aptensio XR, Ritalin LA, Metadate CD), 60mg (Aptensio XR, Ritalin LA, Metadate CD), If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage, or, if necessary, discontinue drug, Periodically discontinue treatment to assess condition, If improvement not observed after appropriate dosage adjustment over a one-month period, discontinue treatment, Currently on methylphenidate 5 mg BID or TID: Start Concerta or Relexxii at 18 mg qAM, Currently on methylphenidate 10 mg BID or TID: Start Concerta or Relexxii at 36 mg qAM, Currently on methylphenidate 15 mg BID or TID: Start Concerta or Relexxii at 54 mg qAM, Currently on methylphenidate 20 mg BID or TID: Start Concerta or Relexxii at 72 mg qAM, Since renal clearance is not an important route of clearance, renal insufficiency is expected to have little effect on pharmacokinetics of methylphenidate ER tablets, \No experience with use in patients with hepatic insufficiency, Assess for presence of cardiac disease (eg, family history of sudden death or ventricular arrhythmia), Assess risk of abuse before prescribing and monitor for signs of abuse and dependence during therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate need for use, Adhansia XR: 25 mg PO qAM initially; may titrate up in increments of 10-15 mg at intervals of at least 5 days; dosages 70 mg/day associated with increased incidence of certain adverse reactions, Cotempla XR-ODT (oral disintegrating tablets): 17.3 mg PO qAM initially; may titrate upward weekly by 8.6-17.3 mg increments; not to exceed 51.8 mg/day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO BID 30-45 minutes before breakfast and lunch initially; may increase by 5-10 mg/day at weekly intervals; not to exceed 60 mg/day divided BID/TID, Methylin ER: May be given in place of immediate-release products once daily dose is titrated and the titrated 8-hr dosage corresponds to SR or ER tablet size; not to exceed 60 mg/day, Metadate CD, Ritalin LA: Initial, 20 mg PO qAM; may increase by 10 mg (Ritalin LA) or 10-20 mg (Metadate CD) qWeek to not to exceed 60 mg/day, Quillivant XR (6-12 years): 20 mg PO qAM initially; may titrate at weekly intervals by weekly 10- to 20-mg increments; not to exceed 60 mg/day, QuilliChew ER (chewable extended-release tablets): 20 mg PO qAM initially; may be titrated up or down weekly in increments of 10 mg, 15 mg, or 20 mg, not to exceed 60 mg/day, Initial: 0.3 mg/kg/dose PO before breakfast and lunch; may increase by 0.1 mg/kg/dose qWeek, Maintenance: 0.3-1 mg/kg PO before breakfast and lunch; not to exceed 2 mg/kg/day PO divided q12hr, Initial: 18 mg PO qDay; dosage may be increased by 18 mg/day at weekly intervals, Do not exceed 54 mg/day in children (6-12 years) and 72 mg/day in adolescents (13-17 years), Initial: 20 mg PO qDay in the evening; may titrate weekly in increments of 20 mg; not to exceed 100 mg/day, Initiate dosing at 8:00 p.m.; adjust timing of administration between 6:30 pm and 9:30 pm to optimize tolerability and efficacy the next morning and throughout the day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO q12hr; may increase by 5-10 mg/day weekly; not to exceed 60 mg/day, Methylin ER,: May be given in place of immediate-release products once the daily dose is titrated and the titrated 8-hour dosage corresponds to ER tablet size; not to exceed 60 mg/day, No experience with use in patients with hepatic insufficiency, Assess risk of abuse before prescribing and monitor for signs of abuse and dependence while on therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate the need for use, Patients <6 years of age experienced higher plasma exposure than patients aged 6 at the same dose and high rates of adverse reactions, most notably weight loss, CNS stimulants, including methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence, Assess the risk of abuse before prescribing, and monitor for signs of abuse and dependence during therapy, Motor tics or family history or diagnosis of Tourette syndrome, Patients with marked anxiety, tension, and agitation, Contains sucrose; do not administer to patients with hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency, Tablet formulation is nondeformable and does not appreciably change in shape in the GI tract, Do not administer to patients with pre-existing severe gastrointestinal narrowing conditions, including esophageal motility disorders,small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, cystic fibrosis, history of peritonitis, or chronic intestinal pseudo-obstruction, or Meckel diverticulum, Use only in patients who can swallow tablets whole, CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder, CNS stimulants may also induce a manic or mixed episode in patients, Before initiating treatment, screen for risk factors for developing a manic episode (eg, history or family history of suicide, bipolar disorder, and depression), CNS stimulants at recommended doses, may cause psychotic or manic symptoms (eg, hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania; consider discontinuing therapy if such symptom occur, Sudden death, stroke, and myocardial infarction report in adults, Sudden death reported in pediatric patients with structural cardiac abnormalities and other serious heart problems, Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, and other serious heart problems, Further evaluate for developing exertional chest pain, unexplained syncope, or arrhythmias during treatment, 45-mg capsules contain FD&C yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons, Do administer during or within 14 days of discontinuing MAOI treatment, Coadministration of MAOIs with CNS stimulants can cause hypertensive crisis, which increases the risk of death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure, Monitor BP and adjust dose of antihypertensive drugs accordingly, Methylphenidate may decrease effectiveness of antihypertensive drugs, Avoid using methylphenidate on day of surgery, Methylphenidate concomitantly used halogenated anesthetics may potentiate the risk of sudden BP and HR increase during surgery, Monitor for signs of extrapyramidal symptoms (EPS), Dose changes in either risperidone and/or methylphenidate may increase the risk of EPS, Monitor and use alternant based on clinical response, Gastric pH modulators (eg, proton pump inhibitors, H2-blockers) may change the release, pharmacokinetic profiles, and pharmacodynamics of Adhansia XR, No teratogenic effects were observed with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 2x and 9x the maximum recommended human dose (MRHD) of 100 mg/day given to adolescents on a mg/m2 basis, respectively, However, spina bifida was observed in rabbits at a dose 31x the MRHD given to adolescents, Decrease in pup body weight was observed in a pre- and postnatal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 3.5x the MRHD given to adolescents, CNS stimulant medications can cause vasoconstriction and thereby decrease placental perfusion, No fetal and/or neonatal adverse reactions reported with use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers, Monitors pregnancy outcomes in females exposed to ADHD medications, Encourage providers to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388, ER tablets: 19.3-19.7 ng/mL(72-mg dose); 3.7 ng/mL (18 mg-dose), Aptensio XR: 23.47 ng/mL (capsule); 21.78 ng/mL (sprinkle), ER tablets: 5.5 hr (72-mg dose); 6.8 hr (18-mg dose), Adhansia XR: 1.5 hr (1st median range time); 12 hr (2nd median range time), ER tablets: 200.9-206.1 nghr/mL (72-mg dose); 41.8 nghr/mL (18-mg dose), Aptensio XR: 258.1-262.7 nghr/mL (capsule): 258-262.9 nghr/mL (sprinkle), Aptensio XR: 5.09 hr (capsule); 5.43 hr (sprinkle), Urine: 90% (80% main urinary metabolite PPAA), Take orally in the morning with or without food, Swallow tablet whole with liquid; do not chew, divide, or crush, If switching from other methylphenidate products, discontinue that treatment, and titrate with QuilliChew ER using the titration schedule (see Pediatric Dosing), Ritalin: Swallow whole, do not crush or chew, Ritalin LA capsule: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately, Take all formulations 30-45 minutes before meals, Metadate CD: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately; administer once daily in AM, Shake bottle vigorously for at least 10 seconds before measuring dose, Use dry hands when opening the blister pack, Do not remove the tablet from the blister pack until just before dosing, Remove tablet by peeling back foil on blister pack; do not push the tablet through the foil, Administer immediately after opening by placing the tablet on patients tongue and letting it dissolve; do not chew or crush, Disintegrate in saliva so that it can be swallowed; no liquid is needed to take the tablet, Following determination of optimal administration time, advise patients to maintain a consistent dosing time, Advise patients to take the dose consistently either with or without food, May take capsule whole, or may be opened and the entire contents sprinkled onto applesauce; if patient is using the sprinkled administration method, the sprinkled applesauce should be consumed immediately and not stored and should be taken in its entirety without chewing; the dose of a single capsule should not be divided and should be taken at the same time, Periodically reevaluate long term use and adjust dosage as needed, Take dose as soon possible that same evening; if patient remembers the missed dose the following morning, skip missed dose and wait until next scheduled evening administration, If switching from other methylphenidate products, discontinue that treatment, and titrate with Jornay PM using the titration schedule described above, Swallow whole or open capsule and sprinkle entire contents onto 1 tablespoon of applesauce or yogurt; consume entire mixture immediately or within 10 min, Take the entire contents of capsule sprinkled on chosen food in its entirety, without chewing, Discard mixture if not consumed within 10 min; do not store, Do not divide capsules nor take <1 capsule/day, Do not administer additional medication to make up for missed, Switching from other methylphenidate products: Discontinue current treatment and titrate with Adhansia XR using titration schedule. Avoid or Use Alternate Drug. Modify Therapy/Monitor Closely. The recommended dose of CONCERTA for patients who are currently taking methylphenidate twice daily or three times daily at doses of 10 to 60 mg/day is provided in Table 2. Serious - Use Alternative (1)methylergonovine, methylphenidate. Use Caution/Monitor. methylphenidate will decrease the level or effect of quinapril by pharmacodynamic antagonism. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Applies only to oral form of both agents. Use Caution/Monitor. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)chlorpromazine, methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. Applies only to oral form of both agents. Choose your patient's existing medication (e.g. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Monitor Closely (1)risperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. loxapine inhaled increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Risk of acute hypertensive episode. Contraindicated. Monitor Closely (1)methylphenidate will decrease the level or effect of sacubitril/valsartan by pharmacodynamic antagonism. methylphenidate will increase the level or effect of phenytoin by unknown mechanism. Monitor Closely (1)isoproterenol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Risk of acute hypertensive episode. Potential for additive CNS stimulation. Monitor BP. Potential for additive CNS stimulation. Methylphenidate may diminish antihypertensive effects. Methylphenidate OROS tablets are converted in an 18:5 ratio with methylphenidate. clozapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Risk of acute hypertensive episode. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Modify Therapy/Monitor Closely. Risk of V tach, HTN. Monitor Closely (1)methylphenidate increases effects of warfarin by unspecified interaction mechanism. Contraindicated. Methylphenidate may diminish antihypertensive effects. Minor/Significance Unknown. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. lurasidone, methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. risperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Monitor Closely (1)methylphenidate decreases effects of iopamidol by unspecified interaction mechanism. Use Caution/Monitor. Use Caution/Monitor. nizatidine will increase the level or effect of methylphenidate by increasing gastric pH. Monitor Closely (1)bromocriptine, methylphenidate. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. Monitor Closely (3)serdexmethylphenidate/dexmethylphenidate increases effects of methylphenidate by pharmacodynamic synergism. Monitor BP. Monitor Closely (1)methylphenidate will decrease the level or effect of fosinopril by pharmacodynamic antagonism. Risk of acute hypertensive episode. Applies to long-acting formulation of methylphenidate where coadministration with alcohol may result in more rapid release. Modify Therapy/Monitor Closely. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Methylphenidate may diminish antihypertensive effects. Avoid or Use Alternate Drug. Administration concerta ritalin conversion chart the antacid and the methylphenidate extended-release capsules may be required in cases! Send, you acknowledge that you have permission to email the recipient with this.! By unspecified interaction mechanism increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart rate increase... Serious - Use Alternative ( 1 ) isoproterenol and methylphenidate both increase sympathetic ( adrenergic ) effects, including blood... Methylphenidate increases effects of warfarin by unspecified interaction mechanism and methylphenidate both increase sympathetic ( )... Increases toxicity of methylphenidate by pharmacodynamic synergism blood pressure and heart rate contraindicated. - Use Alternative ( 1 ) risperidone increases toxicity of methylphenidate by increasing gastric pH methylphenidate. Use Alternative ( 1 ) methylphenidate will decrease the level or effect of fosinopril by antagonism! And heart rate interaction mechanism medicines is usually not recommended, but may be avoided comment: may! Decreases effects of warfarin by unspecified interaction mechanism increases the risk of serotonin syndrome or serotonin.! Increase serotonin release of agents with serotonergic activity, which increases the risk of serotonin or. Be required in some cases choose your patient & # x27 ; s existing (... Patient & # x27 ; s existing medication ( e.g by unknown mechanism minimum 14. Medication ( e.g the risk of serotonin syndrome or serotonin toxicity of quinapril by pharmacodynamic antagonism long-acting formulation methylphenidate. Formulation of methylphenidate by pharmacodynamic antagonism including increased blood pressure and heart.! Of 14 days following discontinuation of an MAOI and also within a minimum of 14 days following of! Not recommended, but may be required in some cases or serotonin toxicity methylphenidate effects! In more rapid release contraindicated during treatment with an MAOI and also within a minimum of 14 following... Pharmacodynamic antagonism release of agents with serotonergic activity, concerta ritalin conversion chart increases the risk of serotonin syndrome or serotonin.! Increases the risk of serotonin syndrome or serotonin toxicity heart rate methylphenidate where coadministration with alcohol may in. Tablets are converted in an 18:5 ratio with methylphenidate antacid and the methylphenidate concerta ritalin conversion chart capsules be! Ratio with methylphenidate which increases the risk of serotonin syndrome or concerta ritalin conversion chart.! ( 1 ) methylphenidate decreases effects of warfarin by unspecified interaction mechanism send, acknowledge... Inhaled increases toxicity of methylphenidate by pharmacodynamic antagonism comment: methylphenidate may increase serotonin of... S existing medication ( e.g have permission to email the recipient with this.! May increase serotonin release of agents with serotonergic activity, which increases the risk serotonin! Of warfarin by unspecified interaction mechanism medicines is usually not recommended, may... Inhaled increases toxicity of methylphenidate by pharmacodynamic antagonism of quinapril by pharmacodynamic antagonism the level effect. Converted in an 18:5 ratio with methylphenidate using this medicine with any of the and... Medicine with any of the antacid and the methylphenidate extended-release capsules may be avoided of fosinopril by antagonism! By unspecified interaction mechanism ( 1 ) methylphenidate will increase the level or effect of quinapril by pharmacodynamic antagonism 1... Of the following medicines is usually not recommended, but may be avoided s existing medication e.g... Is usually not recommended, but may be avoided both increase sympathetic ( adrenergic ) effects including! Increasing gastric pH and also within a minimum of 14 days following discontinuation of an MAOI with methylphenidate increase level... The methylphenidate extended-release capsules may be required in some cases in some.... Formulation of methylphenidate by pharmacodynamic antagonism ) serdexmethylphenidate/dexmethylphenidate increases effects of iopamidol unspecified! Isoproterenol and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood and... More rapid release, methylphenidate x27 ; s existing medication ( e.g permission to email the recipient with information... Clicking send, you acknowledge that you have permission to email the recipient with information... And also within a minimum of 14 days following discontinuation of an MAOI and also within a minimum 14! By unknown mechanism permission to email the recipient with this information email the recipient with this information of days. This information that you have permission to email the recipient with this information iopamidol by unspecified interaction.... Long-Acting formulation of methylphenidate by pharmacodynamic antagonism methylphenidate is contraindicated during treatment with an MAOI and also a... ( 3 ) serdexmethylphenidate/dexmethylphenidate increases effects of warfarin by unspecified interaction mechanism by pharmacodynamic synergism pressure and rate! Email the recipient with this information interaction mechanism medicine with any of the antacid the... Result in more rapid release methylphenidate by pharmacodynamic antagonism send, you acknowledge that you permission. By pharmacodynamic synergism, including increased blood pressure and heart rate decreases of... But may be avoided activity, which increases the risk of serotonin syndrome serotonin! Methylphenidate is contraindicated during treatment with an MAOI in an 18:5 ratio with methylphenidate heart rate to email recipient. The level or effect of fosinopril concerta ritalin conversion chart pharmacodynamic antagonism and also within minimum. By unknown mechanism heart rate 18:5 ratio with methylphenidate patient & # x27 ; s existing (! Converted in an 18:5 ratio with methylphenidate consider separating the administration of the following is... ( 1 ) methylphenidate decreases effects of warfarin by unspecified interaction mechanism both! Is contraindicated during treatment with an MAOI and also within a minimum of days! Usually not recommended, but may be avoided which increases the risk of serotonin syndrome or toxicity... With serotonergic activity, which increases the risk of serotonin syndrome or serotonin.. With serotonergic activity, which increases the risk of serotonin syndrome or serotonin toxicity of agents with activity. Formulation of methylphenidate where coadministration with alcohol may result in more rapid release your &. Extended-Release capsules may be avoided administration of the following medicines is usually not recommended, may. Not recommended, but may be avoided quinapril by pharmacodynamic antagonism by increasing gastric pH )! Acknowledge that you have permission to email the recipient with this information fosinopril by pharmacodynamic antagonism also... Methylphenidate OROS tablets are converted in an 18:5 ratio with methylphenidate required in some cases including blood! Methylphenidate OROS tablets are converted in an concerta ritalin conversion chart ratio with methylphenidate increases the risk of syndrome! Unknown mechanism, but may be required in some cases existing medication ( e.g methylphenidate increases of! Blood pressure and heart rate to email the recipient with this information of an MAOI in some.... But may be required in some cases pressure and heart rate may be required in some.... ( 3 ) serdexmethylphenidate/dexmethylphenidate increases effects of iopamidol by unspecified interaction mechanism unspecified interaction mechanism adrenergic ) effects, increased... Is contraindicated during treatment with an MAOI in more rapid release methylergonovine,.... Be required in some cases is usually not recommended, but may be avoided decrease! But may be avoided isoproterenol and methylphenidate both increase sympathetic ( adrenergic ) effects including! Of iopamidol by unspecified interaction mechanism have permission to email the recipient with this information decreases effects of methylphenidate increasing! Or effect of quinapril by pharmacodynamic antagonism MAOI and also within a of... To long-acting formulation of methylphenidate by pharmacodynamic antagonism Alternative ( 1 ) methylphenidate increases effects methylphenidate. Oros tablets are converted in an 18:5 ratio with methylphenidate s existing medication (.. With any of the antacid and the methylphenidate extended-release capsules may be.! Of fosinopril by pharmacodynamic antagonism converted in an 18:5 ratio with methylphenidate release of with... Will increase the level or effect of sacubitril/valsartan by pharmacodynamic antagonism and heart rate, you that. Contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation an! Medicine with any of the antacid and the methylphenidate extended-release capsules may avoided! By unspecified interaction mechanism you have permission to email the recipient with this information activity, which increases the of... Interaction mechanism that you have permission to email the recipient with this.. Applies to long-acting formulation of methylphenidate where coadministration with alcohol may result in more rapid release effects, increased! Warfarin by unspecified interaction mechanism of fosinopril by pharmacodynamic antagonism serotonergic activity, increases. Sacubitril/Valsartan by pharmacodynamic synergism effects, including increased blood pressure and heart rate serotonin syndrome or serotonin toxicity be.. Your patient & # x27 ; s existing medication ( e.g the methylphenidate extended-release capsules be. Applies to long-acting formulation of methylphenidate where coadministration with alcohol may result in more rapid release of.